ES2548442T3 - Reovirus que tienen secuencias modificadas - Google Patents

Reovirus que tienen secuencias modificadas Download PDF

Info

Publication number
ES2548442T3
ES2548442T3 ES08733587.3T ES08733587T ES2548442T3 ES 2548442 T3 ES2548442 T3 ES 2548442T3 ES 08733587 T ES08733587 T ES 08733587T ES 2548442 T3 ES2548442 T3 ES 2548442T3
Authority
ES
Spain
Prior art keywords
residue
leu
seq
val
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08733587.3T
Other languages
English (en)
Spanish (es)
Inventor
Matthew C. Coffey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolytics Biotech Inc
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39758956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2548442(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of ES2548442T3 publication Critical patent/ES2548442T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES08733587.3T 2007-03-12 2008-03-11 Reovirus que tienen secuencias modificadas Active ES2548442T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89442507P 2007-03-12 2007-03-12
US894425P 2007-03-12
US98956807P 2007-11-21 2007-11-21
US989568P 2007-11-21
PCT/CA2008/000483 WO2008110004A1 (en) 2007-03-12 2008-03-11 Reoviruses having modified sequences

Publications (1)

Publication Number Publication Date
ES2548442T3 true ES2548442T3 (es) 2015-10-16

Family

ID=39758956

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08733587.3T Active ES2548442T3 (es) 2007-03-12 2008-03-11 Reovirus que tienen secuencias modificadas

Country Status (16)

Country Link
US (5) US7803385B2 (cg-RX-API-DMAC7.html)
EP (2) EP2132315B1 (cg-RX-API-DMAC7.html)
JP (1) JP5577103B2 (cg-RX-API-DMAC7.html)
KR (1) KR101647843B1 (cg-RX-API-DMAC7.html)
CN (1) CN103710359A (cg-RX-API-DMAC7.html)
AR (1) AR066395A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008226291B2 (cg-RX-API-DMAC7.html)
CA (1) CA2678721C (cg-RX-API-DMAC7.html)
DK (1) DK2132315T3 (cg-RX-API-DMAC7.html)
ES (1) ES2548442T3 (cg-RX-API-DMAC7.html)
IL (4) IL200353A (cg-RX-API-DMAC7.html)
MX (2) MX2009009598A (cg-RX-API-DMAC7.html)
SG (1) SG191602A1 (cg-RX-API-DMAC7.html)
TW (1) TW200904979A (cg-RX-API-DMAC7.html)
WO (1) WO2008110004A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200905951B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
EP2132315B1 (en) * 2007-03-12 2015-07-15 Oncolytics Biotech Inc. Reoviruses having modified sequences
MX2010003556A (es) * 2007-10-22 2010-04-21 Oncolytics Biotech Inc Regimen de tratamiento para trastornos proliferantes.
WO2009143610A1 (en) * 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
JP2011520994A (ja) * 2008-05-27 2011-07-21 オンコリティクス バイオテク，インコーポレーテッド 腫瘍崩解性レオウイルス療法中の炎症性サイトカイン産生の排除
MX2010014555A (es) * 2008-06-26 2011-04-27 Ceva Sante Animale Sa Reoviridae aviar unico.
FR2939807B1 (fr) * 2008-12-11 2010-12-17 Biomerieux Sa Nouveau reovirus isole, procedes et kits de detection
US9395356B2 (en) 2009-10-02 2016-07-19 The National Veterinary Institute Piscine reovirus immunogenic compositions
CN103347535B (zh) 2010-12-02 2015-11-25 昂科利蒂克斯生物科技公司 液体病毒制剂
EP2646052B1 (en) 2010-12-02 2017-03-29 Oncolytics Biotech Inc. Lyophilized viral formulations
SG194449A1 (en) * 2011-04-29 2013-12-30 Oncolytics Biotech Inc Methods of purifying viruses using gel permeation chromatography
ES2796950T3 (es) * 2013-11-15 2020-11-30 Oncolytics Biotech Inc Virus oncolíticos y regímenes reforzados para tratamiento de cáncer
US9660989B1 (en) 2014-01-31 2017-05-23 Google Inc. Internet-wide identity management widget
WO2017141942A1 (ja) 2016-02-16 2017-08-24 国立大学法人大阪大学 線維化を治療するための医薬組成物
WO2019237063A1 (en) * 2018-06-07 2019-12-12 Emory University Modified reoviruses, particles, and uses in treating proliferative disorders
KR102401077B1 (ko) 2019-01-25 2022-05-24 바이로큐어 주식회사 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2020227245A1 (en) * 2019-05-03 2020-11-12 Kansas State University Research Foundation Immunogenic compositions for novel reassortant mammalian ortheovirus from pigs
JP2024500164A (ja) * 2020-12-22 2024-01-04 バイロキュア インコーポレイテッド 新規な改変レオウイルス及びその用途
KR20220090467A (ko) * 2020-12-22 2022-06-29 바이로큐어 주식회사 신규한 변형 레오바이러스 및 이의 용도
US20250154204A1 (en) * 2021-09-24 2025-05-15 Virocure, Inc. Novel reovirus-based vaccine platform and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
ES2347523T3 (es) 2000-11-09 2010-11-02 Oncolytics Biotech, Inc. Metodos para el tratamiento de trastornos proliferativos celulares.
AU2002220416A1 (en) 2000-12-01 2002-06-11 University Of Ottawa Oncolytic virus
CA2437962C (en) 2001-03-16 2005-11-15 Oncolytics Biotech Inc. Method of extracting virus from cell culture
US7163678B2 (en) 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
AU2005257107A1 (en) 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing dendritic cell having RNA virus transferred thereinto
EP1917351A4 (en) * 2005-08-01 2009-12-16 Univ Technologies Int ATTENUATED REOVIRUS
WO2008009115A1 (en) 2006-07-18 2008-01-24 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
EP2132315B1 (en) 2007-03-12 2015-07-15 Oncolytics Biotech Inc. Reoviruses having modified sequences
JP2011520994A (ja) * 2008-05-27 2011-07-21 オンコリティクス バイオテク，インコーポレーテッド 腫瘍崩解性レオウイルス療法中の炎症性サイトカイン産生の排除
EP2646052B1 (en) * 2010-12-02 2017-03-29 Oncolytics Biotech Inc. Lyophilized viral formulations
CN103347535B (zh) * 2010-12-02 2015-11-25 昂科利蒂克斯生物科技公司 液体病毒制剂

Also Published As

Publication number Publication date
US10039827B2 (en) 2018-08-07
US20200237917A1 (en) 2020-07-30
HK1132761A1 (en) 2010-03-05
KR101647843B1 (ko) 2016-08-11
AU2008226291B2 (en) 2014-01-16
JP2010520758A (ja) 2010-06-17
AR066395A1 (es) 2009-08-19
DK2132315T3 (en) 2015-10-19
US20110020288A1 (en) 2011-01-27
SG191602A1 (en) 2013-07-31
US20080226602A1 (en) 2008-09-18
WO2008110004A1 (en) 2008-09-18
CA2678721C (en) 2018-02-13
IL200353A (en) 2017-07-31
IL221701A0 (en) 2012-10-31
EP2132315B1 (en) 2015-07-15
AU2008226291A1 (en) 2008-09-18
MX346950B (es) 2017-04-06
US20090035278A2 (en) 2009-02-05
US20180344853A1 (en) 2018-12-06
EP2132315A1 (en) 2009-12-16
KR20090125103A (ko) 2009-12-03
IL221702A0 (en) 2012-10-31
US20140186301A1 (en) 2014-07-03
US11246930B2 (en) 2022-02-15
ZA200905951B (en) 2010-11-24
IL200353A0 (en) 2011-08-01
CN103710359A (zh) 2014-04-09
US8691241B2 (en) 2014-04-08
JP5577103B2 (ja) 2014-08-20
US10596260B2 (en) 2020-03-24
MX2009009598A (es) 2009-09-21
CA2678721A1 (en) 2008-09-18
EP2952583A1 (en) 2015-12-09
TW200904979A (en) 2009-02-01
AU2008226291A2 (en) 2009-10-08
IL221700A0 (en) 2012-10-31
EP2132315A4 (en) 2011-10-05
US7803385B2 (en) 2010-09-28

Similar Documents

Publication Publication Date Title
ES2548442T3 (es) Reovirus que tienen secuencias modificadas
Shamoo et al. Crystal structure of the two RNA binding domains of human hnRNP A1 at 1.75 Å resolution
Bax et al. X-ray analysis of βB2-crystallin and evolution of oligomeric lens proteins
Chu et al. Tropomyosin is the major mollusk allergen: reverse transcriptase polymerase chain reaction, expression and IgE reactivity
Fan et al. Structural basis of diverse sequence-dependent target recognition by the 8 kDa dynein light chain
Walter et al. Molecular cloning and sequence of cDNA encoding polyoma medium tumor antigen-associated 61-kDa protein.
Weiss et al. Comparative sequence analysis of the complete human sarcomeric myosin heavy chain family: implications for functional diversity
Adams et al. Binding of myosin I to membrane lipids
Steinert et al. Keratin intermediate filament structure: crosslinking studies yield quantitative information on molecular dimensions and mechanism of assembly
Marino et al. Complement in urochordates: cloning and characterization of two C3-like genes in the ascidian Ciona intestinalis
Bardele Functional and phylogenetic aspects of the ciliary membrane: a comparative freeze-fracture study
Ahne et al. Comparative sequence analyses of sixteen reptilian paramyxoviruses
Ono et al. Production and characterization of recombinant human Ku antigen
CZ20001963A3 (cs) Peptidy obsahující citrulin rozeznaný sérem revmatické artritidy jako prostředky pro diagnózu a léčbu
Ruiz Carrillo et al. Structure of human Rack1 protein at a resolution of 2.45 Å
Yoshida et al. Translocation of HSP27 and MKBP in ischemic heart
Glele‐Kakai et al. Epidemiological studies of spectrin mutations related to hereditary elliptocytosis and spectrin polymorphisms in Benin
Romac et al. The U1 small nuclear ribonucleoprotein (snRNP) 70K protein is transported independently of U1 snRNP particles via a nuclear localization signal in the RNA-binding domain
Agou et al. Polyanion-Induced. alpha.-Helical Structure of a Synthetic 23-Residue Peptide Representing the Lysine-Rich Segment of the N-Terminal Extension of Yeast Cytoplasmic Aspartyl-tRNA Synthetase
Yu et al. Phylogeny and evolution of the Drosophila nasuta subgroup based on mitochondrial ND4 and ND4L gene sequences
Liu et al. Rapid characterization of avian reoviruses using phylogenetic analysis, reverse transcription-polymerase chain reaction and restriction enzyme fragment length polymorphism
Poyarkov et al. Phylogeography of the Siberian newt Salamandrella keyserlingii by mitochondrial DNA sequence analysis
Liu et al. Association of HLA class II DRB1, DPA1 and DPB1 polymorphism with genetic susceptibility to idiopathic dilated cardiomyopathy in Chinese Han nationality
Khan et al. An immunoinformatics approach to promiscuous peptide design for the Plasmodium falciparum erythrocyte membrane protein-1
Cereb et al. Molecular analysis of HLA‐B35 alleles and their relationship to HLA‐B15 alleles